Biotron Limited · ASX:BIT
Biotron — Asia Biotech Invest 2013
10 slides from Biotron's conference presentation, Jun 5, 2013
Slide 1: ASX cover letter: Biotron to present at Asia Biotech Invest 2013
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au For personal use only 5 June 2013 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (10 pages by email) Dear Madam BIOTRON TO PRESENT
Slide 2: Biotron Limited - Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) For personal use only Clinical Stage An;viral Drug Development Company Michelle Miller CEO & Managing Director +61 (0) 412 313 329 mmiller@biotron.com.au
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presenta,on may contain forward-‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited and certain of the plans and objec,ves of its management. These statements are statements
Slide 4: Biotron Limited Overview
Biotron Limited Overview • Clinical stage antiviral drug development company For personal use only • Focus on developing novel small molecule drugs • Clinical programs for Hepatitis C virus (HCV) and HIV • Earlier stage programs include Dengue and others • Headquartered in Sydney, Australia • Key re
Slide 5: Advanced Pipeline of Clinical Programs
Biotron -‐ Advanced Pipeline of Clinical Programs VIRAL For personal use only INDICATION DISCOVERY PRE-‐CLINICAL PHASE 1a PHASE 1b PHASE 2a PHASE 2b STATUS TARGET • Ph 2a complete; • Ph 2b (3 mth Hepa;;s C p7 dosing) scheduled for 4Q13 HIV Vpu • Ph 2a complete Hepa;;s C/ Vpu/p7 • Ph 2 in progress
Slide 6: BIT225 and Hepatitis C
BIT225 and Hepa;;s C • New investigational oral drug for treating HCV infection For personal use only • First in class; targets p7 protein – essential for virus assembly and release • Synergistic with IFN/RBV (current treatment) and polymerase inhibitors • Three completed trials: § Phase Ia –Single
Slide 7: BIT225 HCV Phase 2a Clinical Information
BIT225 HCV Phase 2 Clinical Informa;on For personal use only % with End of % with Early Treatment Viroogical Median log Virological Response Treatment reduc;on at Response 35 days (<50IU/ml at 12 Treatment window (<50IU/ml at 48 weeks) weeks) 400 mg BIT225 + -‐4.957 86 100 IFN/RBV 200 mg BIT225 + -
Slide 8: BIT225 and HIV
BIT225 and HIV • BIT225 also has potent anti-HIV activity For personal use only – Unique mode of action targets HIV “hiding” in long-lived reservoir cells • Reservoirs are last of the holy grail in HIV * • No existing drugs target this source of HIV in the body • Phase 2a trial of BIT225 in HIV-infe
Slide 9: Biotron Opportunity
Biotron Opportunity • Documented need for new antiviral drugs For personal use only • Licensing space is very active (Gilead/Pharmasset US$11b deal) • HCV worldwide market ~US$2.8 billion; predicted to reach >US$10 billion • BIT225 - good clinical efficacy against both HCV and HIV • Potential use wi
Slide 10: Key Financials and Facts
Key Financials and Facts BIOTRON ASX Code LIMITED KEY FINANCIALS price BIT history chart Mr Michael Hoy BOARD AND MANAGEMENT Chairman For personal use only Recent Share Price (30 May 2013) A$0.10 Dr Michelle Miller CEO & Managing Director 52 Week High A$0.185 Dr Denis Wade Non-‐Execu;ve Director 52